Stockwinners Market Radar for March 08, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EST FTI Consulting expands partnership with Relativity in Australia - FTI Consulting announced that its Technology segment has expanded its partnership with global legal technology company Relativity to provide the cloud-based e-discovery solution RelativityOne in Australia. Building upon FTI Technology's legacy as one the largest and most prominent e-discovery consulting and services providers in Australia and around the world, this extension of RelativityOne provides clients with more flexibility and control of their matters in Australia and globally. "Our team has a unique position and long-standing track record of excellence in the e-discovery industry in Australia," said Scott Gillard, a Managing Director within FTI Technology based in Brisbane. "Moreover, our global footprint with RelativityOne is one of the largest, providing our clients with consistency and flexibility, which are critical in reducing friction in high-stakes and cross-border matters."

19:15 EST Bionomics reports 'promising' full results analysis from PREVAIL - Bionomics announced the release of a comprehensive analysis of the data from its Phase 2 PREVAIL study to evaluate the efficacy and safety of BNC210, a novel alpha7 nicotinic acetylcholine receptor negative allosteric modulator, for the acute treatment of Social Anxiety Disorder. These data support late-stage development of BNC210 in SAD. The PREVAIL study was designed with the aim of uncovering the best methodological approaches to measure the therapeutic potential of BNC210 in the acute treatment of SAD, a setting with no approved treatments, and evolving understanding of clinical trial methodologies. While PREVAIL did not meet its primary endpoint, the December 2022 topline data readout revealed encouraging trends in the prespecified endpoints that focused on individual phases of the public speaking task. These results supported a post-hoc in-depth analysis of the full dataset to better understand the true potential of the drug and guide late-stage trial design. This full analysis revealed that BNC210's therapeutic potential was not limited to a single task phase but was present throughout the speaking task, including the performance phase of the public speaking challenge and the anticipatory period immediately prior. Moreover, administration of both 225 mg and 675 mg BNC210 doses resulted in therapeutic responses of similar magnitude, which allowed for the data from the two arms to be combined, enhancing the dataset's statistical power.

18:47 EST Piedmont Lithium trading halted, news pending

18:39 EST Apple backs new music startup Gamma - Apple is backing a new music startup called Gamma, which was launched by former Apple Music Global Creative Director Larry Jackson and veteran music executive Ike Youssef. Gamma's launch is also supported with financial backing from Eldridge and A24 to offer artists creative and business services across all artistic and commercial touchpoints. "The power of intellectual property and creative expression cannot be contained to any one format," said Jackson. "The artists shaping today's culture not only create music, but also video, film, podcasts, fashion, and more. They shouldn't have to jump through multiple hoops to express themselves. gamma is built with the flexibility and aptitude that creators need to connect with fans on all formats and across all channels - with transparency and no restriction. We are a progressive media company powered by the best-in-class content distribution and analytics software by way of our Vydia acquisition. And central to its core, gamma is an ideas company." "Larry and Ike's idea for gamma centers on service to the artist," said Todd Boehly, Chairman and CEO of Eldridge. "We are excited to partner with them, Apple, and A24 to build a platform that helps artists deliver exceptional content with fans, and grow the enterprise value of their own brands."

17:39 EST MacroGenics announces sale of TZIELD royalty interest for up to $200M - MacroGenics announced that it has entered into an agreement to sell its royalty interest on future global net sales of TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust for up to $200M. MacroGenics retains its other economic interests related to TZIELD, including future potential regulatory and commercial milestones. Under the terms of the agreement with DRI, MacroGenics will receive a $100M upfront payment for the sale of its single-digit royalty on global net sales of TZIELD. MacroGenics will have the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the company is eligible to receive up to $50M from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes. The company may also receive an additional $50M if TZIELD achieves a certain level of net sales.

17:26 EST MongoDB sees Q1 Atlas revenue flat to down sequentially - Says Q4 Atlas revenue benefitted from "unused commitments." Says Atlas continues to face difficult compare on a year-over-year basis. Guidance taken from Q4 earnings conference call.

17:22 EST Asana CEO planning to purchase up to 30M shares of class A common stock - On the company's quarterly conference call, Asana CEO Dustin Moskovitz said that he is planning to enter into a 10b5-1 trading plan on March 9, 2023 to purchase up to 30M shares of its class A common stock. Moskovitz said he making this move because he personally believes Asana shares are undervalued, given the "scale of opportunity" he sees.

17:21 EST Build-A-Bear declares special cash dividend - Build-A-Bear has declared a special cash dividend of $1.50 per share. The dividend will be paid on April 6 to all stockholders of record as of March 23.

17:05 EST Apogee Enterprises names Matthew Osberg CFO - Apogee Enterprises has selected Matt Osberg as the company's next Executive VP and CFO, effective April 28. Mark Augdahl, who served as interim CFO during the company's search process, will resume his role as VP of Finance for Apogee's Architectural Glass segment. Osberg most recently served as CFO at Helen of Troy Limited, a global consumer products company. He joined Helen of Troy in 2016, and previously served as Senior Vice President of Corporate Finance. Prior to joining Helen of Troy, Matt worked for seven years in finance roles at Best Buy Co.

17:02 EST Helen of Troy CFO Matt Osberg resigns, former CFO Brian Grass named Interim CFO - Helen of Troy announced the resignation of CFO Matt Osberg, effective April 27. Osberg has decided to pursue another opportunity, accepting a position closer to his family in Minnesota. Brian Grass, retired Helen of Troy CFO, is expected to join the company as Senior VP, Assistant CFO on March 21, and will become interim CFO beginning April 28. The company will begin an immediate national search for a new CFO.

17:02 EST Noodles & Company says 16 new company-owned restaurants opened in 2022 - Sixteen new company-owned restaurants opened in 2022. The Company had 461 restaurants at the end of 2022, comprised of 368 company-owned and 93 franchise restaurants.

17:00 EST Noodles & Company says FY22 comparable restaurant sales increased 5.6% - "In 2022, comparable restaurant sales increased 5.6% system-wide, including a 6.0% increase for company-owned restaurants and a 3.4% increase for franchise restaurants. Comparable restaurant sales represent momentum across all sales channels, in addition to increases from higher menu pricing. Company-owned average unit volumes were $1.36M in 2022. Sixteen new company-owned restaurants opened in 2022. The Company had 461 restaurants at the end of 2022, comprised of 368 company-owned and 93 franchise restaurants. Restaurant contribution margin decreased to 13.9% in 2022 compared to 15.9% in 2021. This decrease was primarily driven by inflationary pressures throughout our expense items, partially offset by menu price increases and savings initiatives. In particular, our cost of goods sold increased 250 basis points relative to 2021 due to historic inflation in our protein basket," noted the company.

16:46 EST California DFPI monitoring Silvergate situation 'closely' - The California Department of Financial Protection and Innovation announced that Silvergate Bank, a state-chartered bank under the supervision of the DFPI, has voluntarily begun the process of liquidation. Silvergate Bank is based in La Jolla, California. "The Department of Financial Protection and Innovation is monitoring the situation closely to facilitate the safe and expeditious voluntary liquidation of Silvergate Bank," said DFPI Commissioner Clothilde Hewlett. "The Department is evaluating compliance with all financial laws, as well as safety and soundness obligations, and is working closely with relevant Federal counterparts."

16:40 EST Ramaco Resources still sees 2023 production 3.0-3.5 million tons

16:36 EST MongoDB falls 10% to $206.50 after Q1, FY24 revenue views miss estimates

16:34 EST Silvergate sinks over 50% to below $3 after announcing operations winddown

16:33 EST Silvergate to wind down operations, voluntarily liquidate Silvergate Bank - Silvergate Capital announced its intent to wind down operations and voluntarily liquidate the Bank in an orderly manner and in accordance with applicable regulatory processes. In light of recent industry and regulatory developments, Silvergate believes that an orderly wind down of Bank operations and a voluntary liquidation of the Bank is the best path forward. The Bank's wind down and liquidation plan includes full repayment of all deposits. The Company is also considering how best to resolve claims and preserve the residual value of its assets, including its proprietary technology and tax assets. In connection with the above: Centerview Partners LLC is acting as financial advisor, Cravath, Swaine & Moore LLP is acting as legal advisor and Strategic Risk Associates is providing transition project management assistance. In addition, Silvergate Bank made a decision to discontinue the Silvergate Exchange Network (SEN), which it announced on March 3, 2023 on its public website. All other deposit-related services remain operational as the Company works through the wind down process. Customers will be notified should there be any further changes.

16:23 EST QuidelOrtho receives De Novo FDA authorization for Sofia 2 SARS Antigen+ FIA - QuidelOrtho announced that it has been granted a De Novo request from the U.S. Food and Drug Administration, FDA, allowing the company to market its new Sofia 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance. The test is intended for prescription use only and can be used in point-of-care settings. "As the first company to introduce a rapid antigen test for COVID-19 when the FDA granted Emergency Use Authorization for the Sofia SARS Antigen FIA in May of 2020, we are pleased to again be the first to receive De Novo FDA clearance for our Sofia 2 SARS Antigen+ FIA," said Douglas Bryant, president and CEO of QuidelOrtho Corporation. "With this De Novo authorization, Sofia becomes the predicate device upon which subsequent devices of the same type and intended use will be compared. This designation is a tribute to the incredible ingenuity, commitment to quality, and cohesion of our entire QuidelOrtho team from R&D and regulatory affairs, to design, manufacturing, labeling and packaging. It is a spirit that sustained us through the darkest days of the pandemic and will assure that our rapid testing technologies remain at the forefront of prevention as COVID-19 transitions to its endemic stage."

16:20 EST IMPAC Mortgage to relinquish GSE Seller/Servicer designation - Impac Mortgage Holdings is providing the following business update: "The Company continues to responsibly assess its operating strategies to navigate current market and industry conditions, including business model review and expense reduction initiatives. In December 2022, the Company negotiated a buy-out of its legacy commercial lease for $3.0 million, reducing its office space footprint from 120,000 to 19,000 square feet. The relocation was made possible by the Company's ability to maintain a hybrid and remote workforce both during and following the Covid crisis, thereby minimizing physical office space needs. The new lease term runs through July 31, 2025 with a total expense of approximately $800 thousand over the term of the new lease, as compared to over $8.8 million that remained under the prior lease. In line with its business review and expense reduction initiatives, the Company recently repositioned its retail consumer direct lending division into a mortgage broker fulfillment model. The shift to a broker model allows the Company to originate a variety of products that serve its national consumer base at a reduced cost per loan due to significant expense abatement relative to specialized staffing, operations, technology and business promotion. The broker channel will support an expanded suite of loan products and programs, offering enhanced flexibility with respect to credit, pricing, best in class technology, and product development and maintenance. The Company has partnered with established lenders to ensure its consumers continue to receive an optimized experience. The Company expects Non-QM originations to continue to be the dominant product in the mortgage broker channel. The Company's third-party origination ("TPO") channel, in line with industry cohorts, experienced significant volume and margin deterioration in 2022. These conditions have persisted into the first quarter of 2023. The Company has decided to wind-down operations within the TPO channel. The Company will continue to honor its pipeline and related obligations and commitments to its business-to-consumer and business-to-business partners, as it has done historically. The Company remains in good standing with its warehouse lenders, whole loan take-out investors, regulators, vendors and subservicing counterparties. As a result of the Company's lack of conventional GSE origination volume and servicing rights over the past several years, with no direct GSE deliveries to Fannie Mae or Freddie Mac since 2016 and 2020, respectively, the Company intends to voluntarily relinquish its GSE Seller/Servicer designation which has been suspended during these periods of non-delivery. The Company expects to be a third-party originator to support its broker model as needed."

16:18 EST Cohen & Steers reports preliminary AUM $83.5B as of February 28 - A decrease of $3.8B from assets under management at January 31.

16:17 EST Brookdale Senior Living reports February occupancy - February weighted average occupancy increased 300 basis points year-over-year, from 73.3% in 2022 to 76.3% in 2023. Achieved sixteen consecutive months of year-over-year weighted average occupancy growth. Consistent with pre-pandemic seasonality, first quarter-to-date weighted average occupancy decreased 70 basis points compared to the full fourth quarter.

15:54 EST Shopify President says 'business is rocking' - Speaking earlier at the Morgan Stanley Technology, Media & Telecom Conference, Shopify President Harley Finkelstein said, according to a transcript: "The company is great, the product is great, our growth levers we understand well. And I think notwithstanding some of the some of the reaction to the Q4 print, we were trying to be prudent. And so the business is rocking."

15:05 EST Shopify up over 1% to $43.11 as executives present at conference - Shares of Shopify are up 65c, or 1.5%, to $43.11 in afternoon trading. Morgan Stanley is hosting a fireside chat with Shopify President Harley Finkelstein and CFO Jeff Hoffmeister at its conference this afternoon.

15:00 EST Focus Universal to seek shareholder approval for increased number of shares - Focus Universal announced that its board of directors has approved to include upon the ballot to increase the authorized number of common stock. The company will now seek investor approval to increase its number of shares to enable stock splits in the form of dividend in upcoming annual shareholder meeting. Focus Universal shareholders will vote on this proposed increase in shares on the ballot at the 2022 Annual General Meeting.

14:02 EST Lazard names Raymond McGuire as President - Lazard announced that Raymond McGuire has joined the company as President, effective April 3. McGuire will serve as a member of Lazard's senior leadership team and will be responsible for "further strengthening senior client relationships, attracting talent and expanding Lazard's reach across the world." McGuire previously served as Vice Chairman of Citigroup and Chairman of its Banking, Capital Markets and Advisory business, after 13 years as its Global Head of Corporate and Investment Banking.

13:26 EST North American rail traffic down 4.4% for the week ending March 4 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending March 4. For this week, total U.S. weekly rail traffic was 474,191 carloads and intermodal units, down 6.3% compared with the same week last year. Total carloads for the week ending March 4 were 237,413 carloads, down 1% compared with the same week in 2022, while U.S. weekly intermodal volume was 236,778 containers and trailers, down 11.1% compared to 2022. Four of the 10 carload commodity groups posted an increase compared with the same week in 2022. They included coal, up 3,612 carloads, to 72,903; petroleum and petroleum products, up 1,320 carloads, to 10,523; and motor vehicles and parts, up 995 carloads, to 14,264. Commodity groups that posted decreases compared with the same week in 2022 included grain, down 4,309 carloads, to 20,522; nonmetallic minerals, down 1,312 carloads, to 31,204; and metallic ores and metals, down 1,244 carloads, to 19,124. North American rail volume for the week ending March 4, on 12 reporting U.S., Canadian and Mexican railroads totaled 341,889 carloads, up 1.9% compared with the same week last year, and 311,197 intermodal units, down 10.4% compared with last year. Total combined weekly rail traffic in North America was 653,086 carloads and intermodal units, down 4.4%. North American rail volume for the first nine weeks of 2023 was 5,750,477 carloads and intermodal units, down 2.5% compared with 2022. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) , Union Pacific (UNP), Greenbrier (GBX), Trinity Industries (TRN), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

12:31 EST Xbox game 'Starfield' launches September 6, 2023 - Microsoft's Bethesda announced that upcoming role-playing game "Starfield" will release on September 6, 2023. The game, which is being developed by the studio behind the "Elder Scrolls" and "Fallout" franchises, will release exclusive on PC and Xbox Series X/S and will be available on Game Pass on day one. Reference Link

12:24 EST Datadog says making progress towards recovering all services - Datadog said via Twitter: "We continue progress towards recovering all services. Data ingestion and monitor notifications remain delayed across all data types." Earlier the company said it is "investigating issues causing delayed data ingestion across all data types."

12:00 EST HNI Corporation falls -12.4% - HNI Corporation is down -12.4%, or -$3.71 to $26.23.

12:00 EST Yext rises 12.3% - Yext is up 12.3%, or $1.04 to $9.54.

12:00 EST Arlo Technologies rises 44.3% - Arlo Technologies is up 44.3%, or $1.58 to $5.15.

11:45 EST Roku says Dan Jedda to succeed Steve Loudon as CFO, effective May 1 - Roku (ROKU) earlier announced that Dan Jedda will join the company as CFO, effective May 1. He will report to Anthony Wood, Founder and CEO. Jedda will succeed current CFO Steve Loudon, who announced he was leaving Roku last year. Loudon will work closely with Jedda to ensure a smooth transition when he departs the company in August. Since 2020, Jedda has been the CFO at Stitch Fix (SFIX).

11:18 EST Norfolk Southern to establish regional safety training center in Ohio - Norfolk Southern Corporation announced Wednesday that it will create a new regional training center in Ohio for first responders. Additionally, Norfolk Southern will expand its Operation Awareness & Response program, which travels the company's 22-state network and trains first responders on how to respond safely to rail incidents. Norfolk Southern will partner with community leaders to identify a location for the new facility. The mission of the safety training center will be to provide additional, free training for first responders from Ohio, Pennsylvania, West Virginia, and the greater region. It will also strengthen coordination between railroads and first responders in the event of an emergency response. "These commitments are the direct result of my conversations with Governor DeWine and other leaders, all to better support our first responders and their communities. First responders are often immediately on the scene of a rail incident, and we want to ensure they have the knowledge and tools to work safely and effectively to protect the health and safety of their fellow citizens," said Norfolk Southern CEO Alan Shaw. "I want to reiterate our profound gratitude to the first responders from Ohio, Pennsylvania and West Virginia who rushed to the derailment site on February 3rd."

10:40 EST Nano Dimension highlights 'serious allegations' against Murchinson - Nano Dimension (NNDM) released a statement reiterating serious allegations made by staff of OSC in its case against Mr. Marc Bistricer, his private holding company, Saline Investments, and other market participants to hold them "accountable for an illegal and abusive short selling scheme that violated Ontario securities law and was contrary to the public interest" in connection with a private placement by a public company - Canopy Growth Corporation (CGC) Staff of the OSC, which is Canada's largest securities regulatory authority and similar to the U.S. Securities and Exchange Commission, published the statement of allegations on November 9th, 2022, with the next court hearing planned for March 10, 2023.

10:21 EST Cummins launches Accelera to advance the transition to zero-emissions future - "Cummins announced the launch of Accelera, a new brand for its New Power business unit. Accelera provides a diverse portfolio of zero-emissions solutions for many of the world's most vital industries empowering customers to accelerate their transition to a sustainable future," said the company in a statement. The launch of Accelera is a significant step forward in Cummins' efforts to achieve its Destination Zero strategy, focused on evolving Cummins technologies to reach zero emissions across its product portfolio. Cummins' Destination Zero strategy is rooted in the understanding that multiple solutions are required to achieve industry-wide decarbonization across the diverse applications the company powers. Over the past several years, Cummins has invested more than $1.5B in research and technology, capital and acquisitions to build Accelera's leadership and technological capabilities. Accelera is now a global leader in zero-emissions technologies, providing battery electric and fuel cell electric solutions across commercial and industrial applications with hundreds of electrolyzers generating hydrogen around the world today.

10:00 EST Nine Energy Service falls -10.5% - Nine Energy Service is down -10.5%, or -$1.09 to $9.32.

10:00 EST United Natural Foods falls -32.9% - United Natural Foods is down -32.9%, or -$13.47 to $27.49.

10:00 EST Membership Collective rises 16.6% - Membership Collective is up 16.6%, or $1.04 to $7.30.

09:54 EST Assure Holdings Corp trading resumes

09:49 EST Assure Holdings Corp trading halted, volatility trading pause

09:47 EST HNI Corporation falls -15.9% - HNI Corporation is down -15.9%, or -$4.75 to $25.19.

09:47 EST Montrose Environmental rises 11.0% - Montrose Environmental is up 11.0%, or $4.05 to $40.74.

09:47 EST Arlo Technologies rises 16.5% - Arlo Technologies is up 16.5%, or 59c to $4.16.

09:36 EST Knightscope receives order from Port Authority NY NJ for 3 new K1 Call Boxes - Knightscope announced the receipt of an order from Port Authority NY NJ for 3 new K1 Call Boxes to add to the recently renovated Bayonne Bridge.

09:28 EST Piedmont Lithium down 4% following Blue Orca short report - Piedmont Lithium down 4% to $54.85 in pre-market trading after a short report was published by Blue Orca.

09:27 EST Essential Utilities falls 2% to $40.70 after Spruce Point short report

09:23 EST Oragenics appoints Janet Huffman as CFO - Oragenics (OGEN) announced the appointment of Janet Huffman as CFO, effective March 7. Huffman is a financial executive with more than a dozen years of leadership experience at publicly traded and private healthcare companies. Huffman served as CFO for Trxade Health (MEDS), a Nasdaq-listed company focused on health services IT for retail pharmacies.

09:20 EST CEL-SCI's Multikine Phase 3 cancer study shows 43% survival extension - CEL-SCI Corporation reported new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head and neck, SCCHN. A poster presentation titled "Leukocyte Interleukin Injection immunotherapy followed by radiotherapy extends overall survival n treatment naive locally advanced primary squamous cell carcinoma of the head & neck: the IT-MATTERS Study" was delivered by Eyal Talor, Ph.D., CEL-SCI's Chief Scientific Officer on March 8 at the 10th European Congress on Head & Neck Oncology in Lisbon, Portugal. CEL-SCI plans to submit a Biologics License Application to the U.S. Food and Drug Administration and other regulatory agencies for approval of Multikine nin the treatment of newly diagnosed SCCHN in patients deemed at lower risk for recurrence as defined by National Comprehensive Cancer Network guidelines, representing a patient population of about 210,000 annual cases globally. The new data presented is very important because it focuses exclusively on the patient population from the IT-MATTERS study for which CEL-SCI is seeking regulatory marketing approval, for locally advanced primary head and neck cancer patients scheduled to receive radiotherapy, but not chemotherapy, after surgery. Per the NCCN guidelines, these LR patients typically are recommended to receive only radiotherapy following surgery. The recommended treatment for higher risk for recurrence patients is concurrent chemoradiotherapy after surgery. In the IT-MATTERS study, 44 patients who were determined to be higher risk for recurrence following surgery should have been administered chemoradiotherapy, but received only radiotherapy, and were included in the survival analysis of the IT-MATTERS study initially performed. A more accurate representation of the survival of the intended LR patient population treated with Multikine would have been obtained had the analysis been performed by excluding these 44 patients. At the ECHNO 2023 Congress, we present study data demonstrating the survival and death rate advantages of the patients treated with Multikine over control in the LR population who received only radiotherapy following surgery.

09:18 EST RPM announces strategic education collaboration with Cleveland State University - RPM announced a new strategic academic and vocational partnership between RPM and Cleveland State University, or CSU. The partnership will provide graduate-level education at discounted rates for three current environmental graduate programs: Master of Arts in Environmental Studies, Master of Science in Environmental Engineering, and Master of Science in Environmental Science. The program will launch with the Fall academic semester. The partnership provides a sponsored path of professional development in graduate level environmental coursework for existing RPM EH&S professionals, as well as other operational and technical professionals looking to enhance their knowledge and professional education in the same fields. RPM employees will also be able to take this coursework for continuing education as part of their professional development plan.

09:13 EST Hoth Therapeutics announces collaboration for CLEER-001 Phase 2a clinical trial - Hoth Therapeutics announced the activation of Washington University School of Medicine in St. Louis as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001 for the treatment for rash and skin disorders associated with epidermal growth factor receptor, or EGFR, inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer, or NSCLC, pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer. Hoth is conducting the CLEER-001 clinical trial in the United States.

09:09 EST Novan moves forward with unified corporate branding - Novan announced that its commercial subsidiary, EPI Health, will now unify under one brand name, Novan. "Since the closing of our acquisition of EPI Health in March of 2022, we have made significant progress integrating our organizations into one cohesive business. As of today, we are pleased to move forward as one united brand, Novan, with the unified goal of building a premier medical dermatology company. We believe our integrated business will streamline our pre-commercial activities for berdazimer gel, 10.3%," commented Paula Brown Stafford, President and Chief Executive Officer of Novan.

09:09 EST Borqs Technologies wins project to develop 5G rugged handheld device - Borqs Technologies announced that the Company has won a contract with a prominent North American company to develop and manufacture an Android 5G rugged waterproof handheld device to be deployed in industries such as agriculture, oil and mining, utilities and safety, etc. The device will feature a long-life 5G chipset that can be used until 2030. The Company has signed multiple contracts with the same customer to develop a suite of enterprise class rugged devices which will be launched initially in the North American and European markets, to be followed by other countries. "We are very excited to have won this contract. Borqs has extensive experience and track record in the developing and manufacturing of rugged devices for vertical industries, including intrinsically safe Zone 1 and Zone 2 devices. This new win further confirms Borqs' technology leadership in this area", said Mr. Pat Chan, CEO of Borqs. "We will continue to design and develop suitable devices for our global customers from various industries with our IoT and 5G expertise."

09:08 EST TOP Ships management estimates diluted NAV per share of $5.27 - TOP Ships announced that the Company's management estimates the company's Net Asset Value, based on charter free vessel values, debt and cash as of December 31, 2022 as adjusted for the equity offering that priced on February 14, 2023, to be $286M. This translates into an NAV of $14.05 per common share and $5.27 per common share on a fully diluted basis. The Company also announced that as of today it has 3,834,082 Series F perpetual preferred shares outstanding.

09:07 EST Editas Medicine announces appointment of Aspesi as EVP, CPO - Editas Medicine announced the appointment of Linea Aspesi as the Company's Executive Vice President, EVP, and Chief People Officer, CPO. Aspesi will lead Editas' human resources department and the Company's people strategy in support of its mission and goals. Aspesi joins Editas from Forma Therapeutics, where she served as Chief Human Resources Officer and successfully led the negotiations related to the people elements of the US $1B acquisition of Forma by Novo Nordisk in late 2022.

09:05 EST Skechers and Martha Stewart team on First footwear collaboration - Skechers is giving women a chance to step into lifestyle queen Martha Stewart's shoes with her personalized Spring 2023 capsule, A Day in the Life of Martha-her co-branded footwear collection for living comfortably and beautifully every day. Launched on International Women's Day, the new assortment offers Martha's iconic design stamp on Skechers' most popular slip-ins, slides and sandals for daywear, entertaining and weekend wellness. "This collection is a wonderful way for women to enjoy the shoes that help me feel and do my best, every day of the year and we've built on some of my favorites like Skechers Hands Free Slip-ins and GO WALK ."

09:03 EST Nano Dimension installs 3D Printing System for NASA Marshall - Nano Dimension has installed one of its 3D printing systems - the Admaflex130 - at NASA's Marshall Space Flight Center. Marshall procured the printing system as part of a project to 3D print sodium ion batteries.

09:02 EST Shyft Group debuts Blue Arc Class 5 Crew Cab - The Shyft Group has revealed its latest innovation: an all-electric Class 5 Crew Cab. Daryl Adams, President and CEO of The Shyft Group, introduced the Blue Arc EV Solutions truck during a press conference at NTEA's Work Truck Week 2023 in Indianapolis. Using Shyft's Work Driven Design process, this all-electric vehicle is optimized for crews with a walk-in-van style cab that features a sliding door and weather-protected steps for safe curbside entrance and exit. The spacious interior at 85 inches high and 88.5 inches wide allows crews to walk up into the cab, stand or sit comfortably, and set up a mobile workstation that allows team members to stay plugged in throughout the day.

09:01 EST Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older - The U.S. FDA accepted a supplemental New Drug Application for Jardiance investigating a potential new indication to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company announced.

09:00 EST Inhibikase Therapeutics Inc trading resumes

08:48 EST AIM ImmunoTech announces publication of analysis of ampligen - AIM ImmunoTech announced the publication of a new analysis of the ability of AIM's drug Ampligen to inhibit the spread and replication of Ebola virus disease, which adds to the body of evidence supporting Ampligen's potential as an early-onset prophylactic therapy against human Ebola outbreaks. The data were published in the peer-reviewed journal Antiviral Research, in a manuscript titled, "Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action" and is now available on the Company's website. Ebola virus is a highly infectious and lethal pathogen responsible for sporadic, self-limiting clusters of Ebola virus disease in Central Africa capable of reaching epidemic status. Previously announced data found that Ampligen provided 100% protection against EVD in a mouse model. The newly published analysis supports a dual mechanism of action when Ampligen is used as a prophylactic therapy against EVD. As a TLR3 agonist, the drug induces and enhances the body's innate immunological responses to EBOV infection. Additionally, Ampligen appears to inactivate the EBOV lethal factor, which is believed to be responsible, in part, for the high mortality rate observed in humans, by acting as a "competitive decoy." VP35 is understood to sequester the dsRNA produced by EBOV during its replication, which inhibits the normal innate immune responses to viral infection. These analyses provide supporting evidence to help explain Ampligen's ability to provide protection against EVD in a mouse model at the generally well-tolerated doses frequently used in AIM's clinical trials. Overall, the study data and new analyses give AIM additional confidence in Ampligen's potential as a viable candidate to protect against exposure to EBOV.

08:47 EST Sidus Space awarded new contract for next phase of NASA ASTRA project - Sidus Space was awarded a follow-on agreement for the next phase of NASA's Autonomous Satellite Technology for Resilient Applications, ASTRA, project. During this phase of the ASTRA project, the Autonomous Systems Lab, ASL, team at NASA's Stennis Space Center near Bay St. Louis, Mississippi, will join Sidus Space to integrate ASTRA's autonomous operational on-orbit capabilities on a Sidus-built LizzieSat satellite as the organizations transition to the operational phase of the program. LizzieSat is set to benefit from cutting-edge autonomous operational capabilities that will offer actionable guidance for optimizing its performance, enabling timely maintenance, and more. With the follow-on agreement, Sidus will support development of a NASA Stennis' communication center - the ASTRA Payload Operations Control Center, POCC, at the south Mississippi center. The SSC ASTRA communications POCC will tightly integrate with the Sidus Mission Operations Center, MOC, in Cape Canaveral during on-orbit operations. "We are excited to support the development of the POCC as part of the NASA ASTRA payload mission on LizzieSat," said John Curry, Sidus' Chief Mission Operations Officer. "The POCC will monitor and control day-to-day activities between LizzieSat and NASA's ASTRA payload operations, utilizing proven NASA operations architectures to greatly enhance our mission success and performance."

08:46 EST Omniq announces orders for AI-based parking, security solution - OMNI is deploying it's AI enhanced parking and security solution to four additional airports bringing it's total deployment to 57 Airports across the country.

08:40 EST WidePoint signs reseller agreement with BK Technologies - WidePoint Corporation (WYY) has entered into a reseller agreement with BK Technologies Corporation (BKTI), for the resale of BK's InteropONE PTToC service to the U.S. Department of Homeland Security and the U.S. Department of State. InteropONE is the only PTToC service that enables operational interoperability to first responders through on-demand creation of user groups without requiring network pre-provisioning or gateways.

08:38 EST BK Technologies signs reseller agreement with WidePoint - BK Technologies (BKTI) entered into a reseller agreement with WidePoint Corporation (WYY) for the resale of BK's InteropONE PTToC service to the U.S. Department of Homeland Security and the U.S. Department of State. InteropONE is the only PTToC service that enables operational interoperability to first responders through on-demand creation of user groups without requiring network pre-provisioning or gateways. Under WidePoint's single award Cellular Wireless Managed Services IDIQ contract, WidePoint plans to offer BK's InteropONE service to all DOS and DHS agencies including U.S. Customs and Border Protection, U.S. Immigration and Customs Enforcement, The United States Coast Guard, Federal Emergency Management Agency, Transportation Security Administration, U.S. Secret Service and others.

08:36 EST Grom Social's Top Draw Animation secures assignment to animate Mansour - Grom Social Enterprises announced that its subsidiary Top Draw Animation, TDA, a leading source of premium animation production services for programming shown throughout the world, will lend its animation expertise to season two of Mansour, the emerging animated hit series from Bidaya Media, the production team behind Iftah Ya Simsim, the Arabic language version of Sesame Street. The assignment was announced jointly today by TDA's President, Russell Hicks, and Bidaya Media's CEO, Nabil El Jisr. "With rich characters, compelling storylines and top-shelf animation, Bidaya Media has crafted the perfect hit series," said Hicks. "The dedicated animation experts and artists in our Manila studio are energized to bring season two of Mansour to its growing fan base as the series continues its upward climb. We are thrilled to secure another major win for Top Draw which continues to be a key growth driver for Grom."

08:34 EST Workhorse Group to unveil W56 step van at NTEA Work Truck Show - Workhorse Group announced the formal unveiling of its W56 step van model at the National Truck Equipment Association's Work Truck Week in Indianapolis, IN. The first-look presentation, hosted by Workhorse CEO Rick Dauch, will take place on Wednesday, March 8th at 10:30 a.m. Eastern time.

08:31 EST Melco Resorts & Entertainment enters share repurchase agreement with MIDL - Melco Resorts & Entertainment has entered into a share repurchase agreement with Melco International Development and Melco Leisure and Entertainment Group Limited, a wholly-owned subsidiary of MIDL, pursuant to which the Company will repurchase 40,373,076 of the Company's ordinary shares from Melco Leisure. The aggregate purchase price is $169,836,073.04, which represents a per share price of approximately $4.2067. Closing of the Transaction is subject to the satisfaction of customary conditions. At the closing of the Transaction, the facility agreement with MIDL pursuant to which a $250.0 million revolving loan facility was granted by the Company as lender to Melco International as borrower will also be terminated following the settlement of all amounts due thereunder by MIDL to the Company. A repayment of $200 million by MIDL to the Company was already made in January 2023. In addition to the privately-negotiated Transaction, the Company's previously announced $500 million share repurchase program remains in effect, of which approximately $412 million remains available for future repurchases under the program. Entry into the share repurchase agreement in respect of the Transaction was unanimously approved by the disinterested members of the Audit and Risk Committee of the Company. The Audit and Risk Committee engaged independent financial and legal advisors to assist in its evaluation process. Prior to the Transaction, Melco Leisure owned approximately 727.7 million shares, or approximately 53.1%, of the Company's outstanding shares. Following the Transaction, Melco Leisure will own approximately 687.4 million shares, which, following the cancellation of the repurchased shares, will represent approximately 51.7% of the Company's outstanding shares. The Company will continue to be a subsidiary of MIDL, and the financial results of the Company will continue to be consolidated in the financial statements of MIDL.

08:25 EST Inhibikase Therapeutics Inc trading halted, news pending

08:25 EST Brown-Forman sees FY23 capital expenditures $190M-$210M - Sees FY23 effective tax rate 22%-23%. Sees FY23 gross margin consistent with first half. Sees FY23 organic net sales growth 8%-10%. The company said, "The company anticipates strong growth in fiscal 2023 despite global macroeconomic volatility and geopolitical uncertainties. The rebuilding of finished goods inventories, due to the easing of supply chain constraints, positively impacted results during the first nine months of fiscal 2023. For the full year, the effect of the estimated net change in distributor inventories could range from no impact to a moderate unfavorable impact on results as the company laps significant inventory rebuilding during the fourth quarter of fiscal 2022."

08:21 EST Biomerica launches InFoods IBS test - Biomerica announced the launch of its InFoods IBS test. The test is being performed in a CLIA-certified, and CAP accredited high-complexity laboratory facility and offered as a laboratory developed test. The Company further announced all validation testing necessary for the InFoods IBS product to be offered as an LDT has been completed. The first patient samples have been processed. Following the completion and results from the Company's InFoods IBS clinical trial, Biomerica has received significant interest from Gastroenterology physicians who would like to order the InFoods IBS test for their patients immediately. In the data presented at the ACG annual meeting for the Abdominal Pain Intensity responder endpoint of greater than30% improvement in pain, patients with IBS Constipation and IBS Mixed in the treatment diet arm had a statistically significant improvement over patients in the placebo diet arm. The improvement for patients in the treatment arm versus the placebo arm is considered clinically significant and is similar and, in some cases, better than the current drugs in the market. Robert Carlson is managing the InFoods IBS LDT launch as well as the future phases of the commercialization strategy including national reimbursement and FDA marketing authorization.

08:18 EST Ra Medical Systems' Catheter Precision announces publication of VIVO data - Ra Medical Systems announced that its wholly owned subsidiary, Catheter Precision, Inc., has had new clinical data published for its leading product VIVO, that confirms the perceived benefits of using VIVO in a ventricular ablation program. VIVO is a non-invasive localization system that provides the physician with data about the patient's heart prior to a ventricular ablation. This data is then used by the physician to plan certain aspects of the procedure including where to look for the start of the arrhythmia, which can be a time-consuming process. The newest publication by the Royal Brompton Hospital with lead author Professor Sabine Ernst, confirms that VIVO does reduce mapping time by almost 30%. A reduction in mapping time leads to a total reduction in procedure time, potentially increasing patient safety. In addition, this publication discusses that patients with previous ablations that were unable to be performed were now able to have successful ablation procedures improving treatment options for patients with infrequent ventricular arrhythmias.

08:15 EST Opko Health enters exclusive worldwide license agreement with Merck - OPKO Health (OPK) entered into an exclusive worldwide license and collaboration agreement with Merck (MRK), known as MSD outside the United States and Canada, for the development of MDX-2201, ModeX's preclinical nanoparticle vaccine candidate targeting EBV. Under the terms of the agreement, OPKO will receive an upfront payment of $50M and is eligible for milestone payments associated with progress in the development and commercialization of MDX-2201 of up to $872.5M , as well as royalties on global sales. ModeX and Merck will jointly advance MDX-2201 to an Investigational New Drug application filing, after which Merck will be responsible for clinical and regulatory activities, as well as product commercialization. "Through the acquisition of ModeX, we broadened our technology foundation and expanded our product pipeline into new therapeutic areas," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. "Merck represents the ideal partner to develop and commercialize a new vaccine candidate, and we are particularly proud to enter into this high-potential agreement so soon after completing the ModeX transaction last May."

08:14 EST TeraWulf self-mines 143 bitcoin in February - TeraWulf provided an unaudited monthly production and operations update for February. The company self-mined 143 bitcoin in February with an average production rate of 5 bitcoin per day. Cost of power in February averaged $7.9k per bitcoin produced, or approximately $0.038/kWh, which is in line with the company's targeted power cost of $0.035/kWh across its two mining sites.

08:12 EST Ovid Therapeutics announces publication of studies of OV350 - Ovid Therapeutics announced the publication of multiple preclinical studies of OV350 in Cell Reports Medicine. The preclinical studies indicate that OV350 directly activates the potassium chloride cotransporter isoform 2 target, known as KCC2, and suggest that OV350 confers therapeutic efficacy in resistant epilepsy models and may offer a neuroprotective benefit. "These findings provide us with increased confidence that our unique program of KCC2 activators directly bind to the target and, as a result, may deliver significant seizure reduction in treatment-resistant epilepsies, such as status epilepticus. We continue to further characterize our KCC2 activator compounds across several modes of delivery and explore them in models of epilepsies and other conditions associated with neuronal excitation," said Manoj Malhotra, Chief Medical Officer of Ovid Therapeutics. The paper presents data characterizing the mechanistic target engagement of OV350 and evaluates its potential in several translatable, animal seizure models. Mechanistic Engagement Findings. Several mechanistic studies articulated in Cell Reports Medicine suggest that OV350: Directly binds to the KCC2 co-transporter with high affinity and potentiates KCC2 activity without modifying its plasma membrane accumulation or key regulatory phosphorylation sites. Is brain-penetrant and does not show overt effects on behavior in mice. Increases KCC2 activity in neurons and efficiently reduces Cl- accumulation to moderate hyperexcitability. Potential Anticonvulsant & Neuroprotective Properties: Data published from multiple animal models suggest that OV350, at a consistent studied dose, provided significant anticonvulsant properties. Additionally, when OV350 was prophylactically administered, it appeared to prevent seizures in a mouse model. Results were reported from two validated pharmacological screening models: the convulsant pentylenetetrazole model and the kainate-resistant status epilepticus model. These findings suggest OV350: Terminated ongoing resistant status epilepticus and restored the efficacy of benzodiazepines. Prevents the development of benzodiazepine resistant status epilepticus. Reduces neuronal cell injury and death following status epilepticus.

08:11 EST Esperion says ILEP recommends use of bempedoic acid ahead of PCSK9 inhibitors - Esperion announced publication of updated recommendations from the ILEP which advance bempedoic acid utilization in front of injectable PCSK9 inhibitors. The article, entitled "Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the international lipid expert panel" was published in Progress in Cardiovascular Disease. In 2022, the ILEP published recommendations on management of partial or complete statin intolerant patients, utilizing both ezetimibe and PCSK9i therapy ahead of bempedoic acid. Based on the robustness of the CLEAR Outcomes results, the ILEP now recommends bempedoic acid utilization ahead of PSCK9i therapy, either in combination or after ezetimibe treatment. Highlights from the ILEP recommended pathways on the use of bempedoic acid in patients with very high cardiovascular risk are summarized below: Key ILEP Recommendations in Secondary Prevention Patients: In ASCVD/HeFH patients with baseline LDL-C 110-160 mg/dl, utilize an upfront combination of high intensity statin and ezetimibe, and if LDL-C is still greater than 55 mg/dl, start with bempedoic acid. If patient LDL-C is still greater than 55 mg/dl start with PCSK9i targeted therapy, if available. In ASCVD/HeFH patients with baseline LDL-C greater than160 mg/dl, utilize an upfront combination of high intensity statin and fixed dose combination of bempedoic acid and ezetimibe, and if LDL-C is still greater than 55 mg/dl, start with PCSK9i targeted therapy, if available. Key ILEP Recommendations in Primary Prevention Patients: In very high-risk patients with partial statin intolerance, utilize an upfront combination of high intensity statin and ezetimibe, and if LDL-C is still greater than 55 mg/dl, start with bempedoic acid. If patient LDL-C is still greater than 55 mg/dl start with PCSK9i targeted therapy, if available. In very high-risk patients with complete statin intolerance, utilize an upfront combination of bempedoic acid and ezetimibe, and if LDL-C is still greater than 55 mg/dl, start with PCSK9i targeted therapy, if available.

08:09 EST Lightbridge receives notice of allowance from Canadian IP Office for CANDU - Lightbridge Corporation announced that it has received a Notice of Allowance from the Canadian Intellectual Property, IP, Office for a key patent that covers a fuel assembly design for Canada Deuterium Uranium, CANDU, heavy water reactors with a mixed grid arrangement of Lightbridge metallic fuel rods. Seth Grae, President & Chief Executive Officer of Lightbridge Corporation, commented, "This is an important expansion of Lightbridge's intellectual property around our fuel assembly design being utilized in CANDU reactors. CANDU-type reactors represent an important market for Lightbridge Fuel(TM). Our ongoing fuel development, including future testing and feasibility studies, will help prioritize commercial deployment to the types of reactors that can utilize Lightbridge Fuel the soonest and with the greatest commercial value."

08:09 EST Satixfy, Kythera Space Solutions partner to deliver payload solutions - SatixFy Communications and Kythera Space Solutions announced that they have partnered to deliver advanced payload solutions for LEO constellations. SatixFy's advanced SX-4000 processor drives high performance and flexibility of software defined satellite, or SDS, platforms, delivering on-board regenerative processing capability and on-orbit reconfigurability. Kythera makes the Kythera Operating System, or KOS, the emerging industry standard for dynamically and autonomously managing and optimizing SDS payloads and NextGen SATCOM networks. KOS optimizes payload and network resources, capacity, and service. The partnership leverages Kythera's KOS to manage and optimize SatixFy's SDS payloads, delivering a fully integrated solution that includes the space assets, as well as space and ground segment management and orchestration capabilities for LEO constellation optimization. The combination of SatixFy's advanced payload processor with Kythera's dynamic resource management software will enable customers to reduce overall time-to-market, reduce internal development costs, and increase profitability over the life of their LEO constellations. The combined solution will decrease the operational complexities associated with managing and optimizing complex LEO constellation architectures, increasing operational efficiency while decreasing operational support costs.

08:07 EST HireRight and GryphonHR announce strategic partnership - HireRight and GryphonHR, a Form I-9 and E-Verify compliance solutions provider announced a new partnership that will provide HireRight's customers with access to GryphonHR's I-9 technology and program management solutions. Through this partnership, HireRight customers who utilize its Form I-9 services, including E-Verify, can benefit from GryphonHR's interactive I-9 program dashboards, self-service reporting, customized workflows, auditing capabilities, and real-time platform updates to help meet compliance requirements. "We are always looking for ways to bolster our services to offer our customers innovative background screening solutions," said Guy Abramo, President & CEO of HireRight. "We are proud to partner with GryphonHR to strengthen our I-9 offering, providing our customers with the latest technology and tools to more effectively manage their Form I-9 and E-Verify workflows." "We are thrilled to provide our Form I-9 and E-Verify technology platform to HireRight's customers," said Marc Villella, President of GryphonHR, "Integrating our Form I-9 platform with HireRight's screening services will provide their customers with a streamlined candidate experience that will be a differentiator in the market." GryphonHR was founded by seasoned HR Compliance executives to provide a centralized and secure platform to help employers incorporate compliance into the hiring process for the entire lifecycle of their employees and contractors.

08:06 EST Gol Linhas sees preliminary Q1 capacity up 11%-13% - Sees preliminary Q1 seats up 14%-16%; departures up 14%-16%; average load factor ~82%.

08:04 EST Agilent announces multi-year distribution agreement with Proscia - Agilent announced a multi-year distribution agreement with Proscia to offer a comprehensive digital diagnostic pathology system. Combining Agilent's trusted pathology staining solutions with Proscia's Concentriq Dx enterprise pathology platform will empower pathology labs to transform diagnostic efficiency and quality to improve patient health outcomes. Digital pathology is experiencing a new wave of adoption as laboratories seek to deliver on growing expectations for precision medicine amid a worsening pathologist shortage and rising biopsy volume. In shifting the 150-year-old standard of diagnosis from microscope to whole slide image, digital pathology enables pathologists to increasingly tap into the data contained in stained slides to make more efficient and confident decisions. Pathologists can also share patient cases remotely for peer review in real-time, further improving the quality of diagnosis and the speed of case handling. Proscia's Concentriq Dx scalable enterprise pathology platform powers primary diagnostic workflows from individual labs to even the largest laboratory networks. It offers a pathologist-centric user experience across a digital environment for viewing, managing, and analyzing images.

08:04 EST Gol Linhas cuts FY23 capacity growth outlook to 15%-20% from 20%-25% - Cuts FY23 seats growth outlook to 20%-25% from 25%-30%; departures growth outlook to 20%-25% from 25%-30%; average load factor ~81% vs. ~80% prior. The company updates its financial forecasts to reflect revisions in the level of supply expected for the year 2023 in view of expectations of recovery in corporate demand and impacts on the global chain of aircraft deliveries and the supply chain

07:50 EST United Natural Foods falls 20% to $32.51 after cutting FY23 EPS outlook

07:36 EST Pipestone Energy sees 2024 production 40,000-42,000 boe/d - Sees capex C$220M, FCF C$125M.

07:35 EST Pipestone Energy sees 2023 production 34,000-36,000 boe/d - Sees capex C$245M-C$265M, FCF C$75M-C$95M.

07:35 EST Biogen elects Dorsa as Chair of the Board of Directors - Biogen announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company's 2023 Annual Meeting of Stockholders, scheduled to take place on June 14, 2023. Dorsa will succeed Stelios Papadopoulos, Ph.D., who announced he would not stand for reelection to the Board at the Annual Meeting. Dorsa joined the Biogen Board in 2010.

07:33 EST Bed Bath & Beyond receives $135M from previous equity offering - Bed Bath & Beyond announced the receipt of approximately $135M in gross proceeds, for a cumulative total of $360M through March 7th, upon exercise of preferred stock warrants issued in its previously announced public equity offering. As a reminder, on February 7, the company completed an underwritten public offering which raised initial gross proceeds of $225M and enabled the company to receive up to an additional $800M. The company has used proceeds received to date to repay outstanding revolving loans, creating additional liquidity opportunities to support business operating activities.

07:32 EST Trevi receives notice of allowance from USPTO for nalbuphine ER's method - Trevi Therapeutics announced that on March 7 the USPTO issued a notice of allowance for nalbuphine ER's method of treatment of chronic cough in IPF. Trevi expects the resulting patent will be Orange Book-listable with an anticipated expiration in 2039. Trevi intends to continue to prosecute additional patent applications to further enhance its existing patent estate protecting nalbuphine ER across multiple chronic cough conditions as additional clinical data is generated.

07:29 EST StateHouse joins Cannabis Research Coalition - StateHouse Holdings joined the Cannabis Research Coalition, a collaborative research partnership between The Hemp Mine and Clemson University. The partnership will address cannabis cultivation and postharvest challenges. The CRC partners with cannabis industry stakeholders to advance the exploration of the cannabis plant and implement science-based research to develop the techniques required to create a sustainable, efficient and profitable industry. Using a cooperative research approach, the coalition is able to provide practical answers to the questions that limit the success of the cannabis industry. StateHouse expects to benefit from the coalition's cooperative research model because it will provide the Company's cultivation teams with the tools needed to stay competitive while further enhancing quality. Additionally, StateHouse will have access to exclusive offers from allied trade members; obtain SOPs for production; and participate in monthly and annual conferences and virtual meetings regarding research updates.

07:27 EST Alterity Therapeutics enrolls first patient in Italy in ATH434 Phase 2 trial - Alterity Therapeutics announced the first participant in Italy has been dosed in the Company's Phase 2 clinical trial of ATH434 in Multiple System Atrophy, a rare and highly debilitating Parkinsonian disorder. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA. The study will evaluate the effect of ATH434 treatment on neuroimaging and protein biomarkers to demonstrate target engagement and clinical endpoints to demonstrate efficacy, in addition to assessments of safety and pharmacokinetics. The selected biomarkers, including brain iron and aggregating alpha-synuclein, are important contributors to MSA pathology and are therefore appropriate targets to demonstrate drug activity. Wearable sensors will also be employed to evaluate motor activities that are important to patients with MSA. The study is expected to enroll approximately 60 adults to receive one of two dose levels of ATH434 or placebo. Participants will receive treatment for 12 months which will provide an opportunity to detect changes in efficacy endpoints to optimize design of a definitive Phase 3 study.

07:22 EST Nuvista Energy sees 2023 production 79,000-83,000 boe/d - The company said, "As discussed above, NuVista is pleased to note that operations and performance have been strong while both condensate and natural gas prices have been favorable through 2022. We are in an extremely fortunate position of having top tier assets and economics, and with disciplined execution we have been spending approximately half of free adjusted funds flow on capital to execute our plans. This means that despite the significant moderation of natural gas pricing during the first quarter of 2023, free adjusted funds flow is reduced but still highly positive. We have hedged approximately 35% of projected natural gas production for this summer with floor and ceiling prices of C$4.17/Mcf and $7.31/Mcf. We have less than 2% exposure to AECO prices this summer due our hedges and our diversified sales portfolio. Due to our high condensate weighting, our execution economics remain very strong. As such, we will continue with our capital execution plans unchanged while still returning free adjusted funds flow to shareholders and reducing net debt. Full year production and capital spending guidance is reaffirmed at 79,000 - 83,000 Boe/d and $425 to $450 million, respectively. Due to the continued efficiency gains mentioned above and strong well performance our first quarter volumes are still expected to fall within our previous guidance range of 71,000 - 74,000, but likely near the bottom of the range due to unplanned outages at three separate third party midstream facilities which impacted quarterly production by 1,500 Boe/d. All repairs were completed and the facilities are now back online. Daily production levels have currently reached 78,000 Boe/d due to a number of new wells commencing production, however we are temporarily prevented from increasing production further due to the ongoing restrictions on the NGTL pipeline network in the Upstream James River Area. The restrictions are expected to subside through mid-March, and the remaining three quarters of the year are each expected to average well over 80,000 Boe/d. We intend to continue our track record of carefully directing free adjusted funds flow towards a prudent balance of return to shareholders and debt reduction, while investing in production growth until our existing facilities are filled and debottlenecked to maximum efficiency. NuVista has an exceptional business plan that maximizes free adjusted funds flow and the return of capital to shareholders when our existing facilities are debottlenecked and filled to maximum efficiency at production levels of approximately 100,000 to 105,000 Boe/d. With facilities optimized, returns are enhanced further with corporate netbacks which are expected to grow by approximately $2-$3/Boe due to the efficiencies of scale which will reduce our unit operating, transportation, and interest expenses."

07:19 EST Aflac enhances hospital insurance product to include mental health coverage - Aflac enhanced its hospital insurance product to include income protection for mental health treatment while reducing hospital confinement hour requirements to qualify for benefits. The enhanced product, named "Aflac Choice," is designed to help customers with expenses associated with doctor visits, hospitalizations and mental health treatment that health insurance doesn't cover.

07:18 EST Aslan Pharmaceuticals to host virtual research day on AA - ASLAN Pharmaceuticals announced that it will be hosting a virtual research and development day on Thursday, March 16, 2023. The event will feature Key Opinion Leader Brett King, MD PhD who will discuss the unmet medical need and current limited treatments for patients suffering from alopecia areata, AA. ASLAN's leadership team including Carl Firth PhD, Stephen Doyle, Alex Kaoukhov MD and other members of the senior R&D management team will then provide an update on its recently announced clinical program to investigate farudodstat, a novel, oral inhibitor of the enzyme dihydroorotate dehydrogenase, in a Phase 2 proof-of-concept trial, as a potential first-in-class treatment for AA. ASLAN plans to initiate a proof-of-concept study of farudodstat in AA in the second quarter of 2023.

07:16 EST Gambling.com ready to launch online sports betting in MA with BetMassachusetts - Gambling.com Group (GAMB) announced it has been issued a sports wagering registration by the Massachusetts Gaming Commission, MGC, and is set to provide marketing services to licensed online sports betting operators in the Commonwealth of Massachusetts with the commencement of legal online sports betting on Friday, March 10th, 2023, at 10:00am ET. The Group launched BetMassachusetts.com in March 2022 ahead of the legal online sports betting market in Massachusetts going live to help sports bettors find trusted, comprehensive and up-to-date information on sports betting and legislative updates in the Bay State. With seven approved online sportsbook operators available on day one -- and three more expected at a later date -- access to comparison websites like BetMassachusetts.com enables consumers to read expert reviews of all legal sportsbooks in the state to help them choose their best option. Through its portfolio of websites Gambling.com Group helps operators acquire players, reducing their reliance on more intrusive forms of advertising. In addition to BetMassachusetts.com, the Group is ready to help licensed online gambling operators in Massachusetts with its national and international websites, including Gambling.com, Bookies.com, RotoWire.com and BonusFinder.com, and through the Worcester Telegram & Gazette via its new media partnership with Gannett (GCI)

07:15 EST DT Midstream announces board of director changes - The DT Midstream (DTM) Board of Directors announced the appointment of Angela Archon to its Board of Directors, effective March 7, 2023. Archon, who qualifies as an independent director, will serve as a Class III Director of DT Midstream until the company's 2024 annual meeting of stockholders or until her earlier resignation or removal. Archon's career includes over 30 years at International Business Machines (IBM) where she held various global executive leadership roles. Coinciding with the appointment of Archon, Wright Lassiter III, DT Midstream's Lead Independent Director and Chair of the Corporate Governance Committee, has resigned. Additionally, Stephen Baker has been appointed Lead Independent Director, effective March 7, 2023. Baker, who is also the Chair of the Finance Committee, succeeds Lassiter.

07:13 EST Allegro MicroSystems announces ACS37601 sensor - Allegro MicroSystems announces the release of samples for the ACS37601, an ASIL C safety-rated, high-precision, field current sensor with best-in-class accuracy for traction and auxiliary inverter systems as well as battery management systems in electric vehicles. Designers of inverter and battery management systems are challenged to achieve higher safety targets based on new Automotive Safety Integrity Level requirements.

07:10 EST Dorman Products launches 200 new repair solutions - Dorman Products announced the release of 200 new motor vehicle parts, including 80 aftermarket exclusives and several new products for popular electric vehicles. The new products advance Dorman's mission of providing repair professionals and owners greater freedom to fix passenger, commercial, and recreational vehicles with internal combustion, hybrid, and electric powertrains.

07:07 EST Nuvei sees 20%+ annual y-o-y revenue growth in medium-term - Sees 50%+ adjusted EBITDA margin growth over the long term. Sees capex 4%-6% of revenue over the medium-term

07:03 EST Ideanomics subsidiary starts third phase of facility expansion in Modena - Ideanomics announced that its subsidiary Energica Motor Company has started the third phase of its facility expansion in Modena, Italy. Ideanomics's subsidiary Energica progresses with the next phase of its headquarters expansion in ItalyEnergica will add a new 12,370 square foot facility dedicated to Energica Inside, research and development, and prototype development and testing. Energica is also making progress on expanding its manufacturing and assembly facilities, including a target for automation which will allow the electric motorcycle manufacturer to deliver on increased market demand.

07:02 EST Diversey to be acquired by Solenis for $8.40 per share in cash - Solenis and Diversey Holdings announced they have entered into a definitive merger agreement under which Solenis will acquire Diversey in an all-cash transaction valued at an enterprise value of approximately $4.6B. Upon completion of the merger, Diversey will become a private company. Under the terms of the agreement, Diversey shareholders -- other than shareholders affiliated with Bain Capital Private Equity -- will receive $8.40 per share in cash, which represents a premium of approximately 41.0% over Diversey's closing share price on March 7, 2023, the last full trading day prior to the transaction announcement, and a premium of approximately 59.0% over Diversey's 90-day volume-weighted average price. Bain Capital will receive $7.84 per share in cash and will rollover a portion of its shares of Diversey into an affiliate of Solenis in exchange for common and preferred units of such affiliate. Headquartered in Wilmington, Delaware, Solenis is a manufacturer of specialty chemicals used in water-intensive industries, which was acquired by Platinum Equity in 2021. "The merger presents a unique opportunity to enhance value and create a more diversified business with increased scale, broader global reach, and superior customer service capabilities. It will enable the combined company to grow and provide a number of attractive cross-selling opportunities, including meeting increasing customer demand for water management, cleaning and hygiene solutions," said Phil Wieland, Chief Executive Officer of Diversey. Solenis CEO John Panichella will lead the combined company following the transition and integration. Diversey's Board of Directors formed the Special Committee to evaluate and negotiate the transaction with the assistance of independent financial and legal advisors. Following this process, the Special Committee unanimously determined that the transaction with Solenis is in the best interests of Diversey and its shareholders, and, acting upon unanimous recommendation by the Special Committee, the Diversey Board of Directors unanimously approved the merger and recommended that Diversey shareholders vote in favor of the merger. The Special Committee negotiated the terms of the merger agreement with assistance from its independent financial and legal advisors. In connection with the transaction, Solenis has entered into a support agreement with Bain Capital, pursuant to which Bain Capital has agreed to vote all of its Diversey shares -- which represent approximately 73% of Diversey's outstanding shares -- in favor of the transaction, subject to certain terms and conditions set forth therein. Solenis intends to finance the transaction with a combination of committed debt and equity financing, including the contribution by Bain Capital. The merger is expected to be completed in the second half of 2023, subject to the satisfaction of customary closing conditions, including approval by Diversey shareholders holding a majority of the outstanding shares of the Company and receipt of regulatory approvals. Upon closing of the transaction, Diversey's ordinary shares will no longer be listed on any public market.

07:01 EST Diversey shareholders to receive $8.40 per share in cash in go private deal

06:53 EST HNI Corporation to acquire Kimball International for $485M in cash and stock - HNI Corporation (HNI) and Kimball International (KBAL) announced that they have entered into a definitive agreement under which HNI will acquire all the outstanding shares of Kimball International in a cash and stock transaction valued at approximately $485M. Under the terms of the agreement, Kimball International shareholders will receive $9.00 in cash and 0.1301 shares of HNI common stock for each share of Kimball International common stock they own. As a result of the transaction, Kimball International shareholders will own approximately 10% of the combined company. Following the close of the transaction, the combined company will continue to be led by Jeff Lorenger, HNI's Chairman, President, and Chief Executive Officer. Juster will remain in her current role with Kimball International until the closing to ensure a seamless transition. The combined company will have pro forma annual revenue of approximately $3.1 billion and pro forma adjusted EBITDA of approximately $290 million, inclusive of annual run-rate synergies, based on each company's respective last reported 12 months. The combination is expected to generate $25 million of annual run-rate cost synergies within three years of closing. Based on HNI's closing share price as of March 7, 2023, the last day prior to today's announcement, the total implied per share consideration equals $12.90, representing a premium on Kimball International's 30-day VWAP of 81%. The consideration implies a valuation multiple of approximately 6.8x calendar year 2022 adjusted EBITDA, inclusive of synergies. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close by mid-2023, subject to the approval of Kimball International shareholders, the receipt of required regulatory approval, and the satisfaction of other customary closing conditions.

06:08 EST Adidas extends appointment of CFO Harm Ohlmeyer by three years - The Supervisory Board of adidas AG has extended the appointment of Harm Ohlmeyer as CFO of the company by another three years until the beginning of 2028. Harm Ohlmeyer has been member of the Executive Board of adidas AG since March 2017 and the company's CFO since May 2017. At the same time, the Supervisory Board appointed Arthur Hoeld as Executive Board member, responsible for Global Sales, as of April 1, 2023. Hoeld has been with adidas for 25 years, most recently as Managing Director of the company's EMEA region since 2018. He will succeed Roland Auschel, who has decided to step down from his role, pass on the baton and leave the company after 33 years with adidas, including ten years as an Executive Board member.

06:06 EST Adidas to slash dividend to EUR 0.70, down from EUR 3.30 last year - The adidas Executive and Supervisory Boards will recommend paying a dividend of EUR 0.70 per dividend-entitled share to shareholders at the Annual General Meeting on May 11, 2023 (2022: EUR 3.30). This reflects a payout ratio of 49.2% (2022: 40.9%) of net income from continuing operations and is at the upper end of the target range of between 30% and 50% of net income from continuing operations as defined in adidas' dividend policy.

06:03 EST Nova Vision Acquisition announces extension of combination period - Nova Vision Acquisition Corp. announced that Nova Pulsar Holdings Limited, the company's initial public offering sponsor, has deposited into the company's trust account an aggregate of $75,030.26 in order to extend the period of time the company has to complete a business combination for an additional one month period, from March 10 to April 10. The company issued a promissory note to Sponsor with a principal amount equal to the amount deposited. The promissory note bears no interest and is convertible into the company's units at a price of $10.00 per unit at the closing of a business combination by the company. The purpose of the extension is to provide time for the company to complete a business combination.

05:18 EST Seadrill announces $79M West Neptune term extension - Seadrill announced that the West Neptune has executed approximately six months of term extensions with LLOG Exploration Offshore, in the U.S. Gulf of Mexico. The extensions will commence in direct continuation of the existing term, and will keep the rig busy until Q3 2024, furthering Seadrill and LLOG's long-term association. Total contract value for the extension is approximately $79M.

05:13 EST Fisker names Deftpower European mobility service provider - Fisker named Deftpower, a provider of EV charging software solutions, as Fisker's European mobility service provider. The partnership provides Fisker Ocean owners access to one of Europe's largest aggregated electric vehicle public charging networks. Fisker announces Deftpower as European public charging platform provider with access to leading EU charging network through Fisker Flex Charge App. Deftpower aggregates over 425,000 public charging stations across 900 different charging operators into one convenient, comprehensive charging network that has grown 32% in the past year.